Exclusive worldwide license to an
innovative implantable drug delivery technology
(jan 8 2001)
Debiotech innovates in implantable drug
Jan. 8, 2001: DEBIOTECH, Lausanne/Switzerland,
has secured an exclusive worldwide license to an innovative implantable
drug delivery technology which will be developed in close collaboration
with DEBIO RP, Martigny/Switzerland, for the continuous administration
of drugs through a patent pending biocompatible nanoporous membrane.
new technology, which is perfectly in line with our experience in
micro-technologies, represents an ideal growth of our device activities
in the pharmaceutical business. The extensive know-how of DEBIO
RP in the field of sustained drug delivery will increase our capability
to immediately respond to important demands in this fast growing
market." says Frédéric Neftel, M.D., CEO of DEBIOTECH.
intends to develop this new technology into an implantable device,
which can either be refilled several times through a septum or withdrawn
after use. The biocompatible nanoporous membrane enables sustained
delivery of drugs over weeks to months. The perfectly controlled
pore size of the membrane can be as small as 1nm (1 million times
smaller than 1 millimetre) up to more than 250nm, with over 100
million pores per cm2 and a thickness of 100 micro-metres. The membrane
is obtained by a patented technique and can be modified to adapt
to specific drug delivery requirements. In vitro experiments have
already demonstrated continuous release of Somatostatin over 1 month
in a linear fashion. Other trials are ongoing with different peptides
and anti-cancer drugs.
technology can be easily adapted to potentially every drug by adjusting
the pore size and a proprietary surface treatment. It can also be
rapidly manufactured and tested in-vitro and on animals.
The intent of DEBIOTECH and DEBIO RP is to propose
this new technology, under the name of "DebioSTAR", to
pharmaceutical companies to offer a new range of therapeutic options
and increase the efficacy and/or convenience of continuous therapy
regimens. The first candidates are peptides, hormones, anti-cancer,
NIAS and CNS drugs.